Catalog Advanced Search

Search by Category
Search by Format
Sort By
Search by Type
Search by Keyword
Search by Category
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Contains 2 Component(s) Recorded On: 01/26/2022

    The demand for in-home digital healthcare is headed to a $44 billion all-time high by 2028, according to industry analysts. With this growth, individual businesses will face stress and new challenges. Are you equipped to handle the increased demand?

    The demand for in-home digital healthcare is headed to a $44 billion all-time high by 2028, according to industry analysts. With this growth, individual businesses will face stress and new challenges. Are you equipped to handle the increased demand?

    Melissa Kozak

    Co-Founder/CEO

    Citus Healthcare

    As a post-acute nurse, Melissa saw first-hand the communication and care coordination challenges connecting front line clinical teams with patients, field staff and partners in home-based care. She also recognized that providers were relying on manual processes to communicate and deliver care, causing inefficiencies and decreasing quality of care. Melissa teamed up with a leading healthcare technologist and founded CitusHealth in 2016 to tackle these challenges head on by providing real-time, secure solutions that ensure a high level of care team coordination and patient and family engagement.

    No Disclosures to Report

    Nick Knowlton

    VP Strategic Initiatives

    ResMed

    No Disclosures to Report

  • Contains 4 Component(s), Includes Credits

    On Novemeber 1, 2022 USP released the revised version of General Chapter Pharmaceutical Compounding--Sterile Preparations, which becomes enforceable November 1, 2023.

    On Novemeber 1, 2022 USP released the revised version of General Chapter <797> Pharmaceutical Compounding--Sterile Preparations, which becomes enforceable November 1, 2023. Although revisions were proposed (and subsequently appealed) in previous years, this version will represent a significant change from the 2008 standards which are currently enforceable. Home infusion pharmacies will need to comprehend how the updated standards apply to their sterile compounding operations. This article will cover the significant areas, including: beyond-use dating for categories 1, 2, and 3 CSPs, requirements for clean room personnel qualification and evaluation, the need for a designated person(s) to ensure the sterile environment maintains quality, environmental monitoring changes and the need for increased testing and cleaning.

    Learning Objectives:

    1. Review the latest updates to USP General Chapter <797> compared to the 2008 version which remains enforceable until November 1, 2023. 
    2. Understand the difference between Category 1, 2, and 3 compounded sterile preparations (CSPs) and list the specific requirements for each.
    3. Describe the requirements for personnel qualification and evaluation.
    4. Explain the increased frequencies for environmental monitoring and cleaning.

    Abby Roth, BS, CMQ/OE

    Founder

    Pure Microbiology

    Abby Roth, founder of Pure Microbiology, has over 18 years of experience in supporting the testing and consulting needs of the pharmaceutical, medical device, and compounding industries. Her background in pharmaceutical microbiology includes extensive knowledge of environmental monitoring. Abby served as a USP Compounding EC member during the 2015-2020 cycle. She is an involved member of the Controlled Environment Testing Association (CETA), serving on the Board of Directors, speaking at its annual meetings, and chairing committees for the revision of four CETA Application Guides. Abby has been invited to speak for state boards of pharmacy and for national organizations.

    No Disclosures to Report

  • Contains 4 Component(s), Includes Credits Recorded On: 07/11/2023

    This program will highlight how to perform a sterile compounding gap analysis to start your journey.

    Starting any project can seem like a daunting task. Preparing for the new 2023 version of USP <797> and USP <800> is not small feat. This program will highlight how to perform a sterile compounding gap analysis to start your journey. One major change to the 2023 version is the requirement for a designated person (DP). This session will also highlight who the best individual or individuals may be and how best to ensure their own competency and prepare to manage and handle all aspects of the organization or facilities sterile compounding activities.

    Learning Objectives:

    1. Review the basic elements of performing a GAP analysis in relation to sterile compounding activities.
    2. Identify gaps in current policy and practice and learn how to develop an action plan to ensure compliance by November 1, 2023.
    3. Understand how to create a job description for the designated person (DP) and who best on your team can fill that role.
    4. Differentiate the need for site and corporate level policies for multi-stie organizations.

    Barbara Petroff, MS, RPh, FASHP, BCSCP, FNHIA, CAC, CSPP, IgCP

    Principal

    Shawler Petroff LLC

    Barbara J. Petroff, MS, RPh, FASHP FNHIA, is currently Principal at Shawler Petroff LLC. In addition she is an accreditation surveyor for the Accreditation Commission for Health Care.  She received her BS in pharmacy at Ohio State University and an MS in administration at Central Michigan University. She has worked in several pharmacy arenas including research, hospital, retail and home infusion. Petroff has served ASHP in many capacities. She also serves as Chair of the Sterile Compounding Practice Committee for the National Home Infusion Association. She was awarded certification in sterile compounding (BCSCP) from the Board of Pharmaceutical Specialties.

    No Disclosures to Report

    Daniel Kyes, CPhT

    Regional Pharmacy Training & Quality Specialist

    New England Life Care

    Dan Kyes, CPhT, Regional Pharmacy Training and Quality Specialist for New England Life Care in Portland, ME.  Focus on USP 797/800, The Joint Commission Accreditation, training, continuous quality improvement.  Within my organization I help to create and implement SOPs, and improve workflow using flowcharts. Nationally Certified/Licensed as a pharmacy technician in multiple states.  Member of NHIA Sterile Compounding Practice Committee and Faculty with the Sterile Compounding Clinic.  When I am not in the pharmacy you can find me enjoying the beautiful outdoors with my camper, searching for vintage vinyls or traveling with friends and family.

    No Disclosures to Report

  • Contains 2 Component(s) Recorded On: 03/17/2023

    Celebrate the research that comprises the top 6 posters for the 2024 NHIA Conference.

    Come celebrate this year's excellence in research as we present the 2024 NHIF Outstanding Abstract Achievement Award. This year, we have over 25 posters that will be on display at the Annual Conference and Expo being held March 23-27, 2024. These finalists were chosen as the top 6 to compete for this distinguished award. Each lead author will have 8 minutes to present their research to a panel of industry judges as well as display their poster at the annual conference. The winner will be announced during our third general session on March 26, 2024. 

    Register now as you will not want to miss these innovative and exciting research projects! 

    • Daptomycin vs. Vancomycin: A Cost Comparison in a Regional Home Infusion Pharmacy
    • Diversity, Equity, and Inclusion in Home Infusion
    • Use of a Lipid Screening Tool to Identify Patients at Greater Risk of Infusion Reactions to Lipids in the Home Setting
    • A Retrospective Review of Home Enteral Nutrition Referrals and Denials of Coverage: Implications for Access to Care and Negative Clinical Outcomes
    • Supporting Your Patient Beyond Immunodeficiency: A Dietitian-led Nutrition Pilot Program

    Katherine Yang PharmD, BCPS

    Clinical Pharmacist

    Kaiser Permanente

    Katherine (Katie) Yang earned her Doctor of Pharmacy degree from California Northstate University in 2021. Following graduation, she completed a Postgraduate Year 1 (PGY1) residency at Erie County Medical in Buffalo, NY. After completing her PGY1 residency, Katie began her professional career at Kaiser Permanente, where she currently works as a clinical pharmacist at Kaiser Permanente Regional Home Infusion Pharmacy in Berkeley, California. In this role, she collaborates on an interdisciplinary team within the Hospital at Home Program, to optimize patient care outcomes and enhance medication management strategies.

    No Disclosures to Report

    Christina Ritchey, MS RD LD CNSC FASPEN

    Clinical Program Manager

    Optum Infusion Pharmacy

    Home Parenteral Nutrition Workshop Take Off: A Pilot Program for Patient Support 

    Christina Ritchey, MS, RD, LD, CNSC, FASPEN is a Clinical Program Manager at Optum Infusion Pharmacy. She is a Registered Dietitian and Certified Nutrition Support Clinician, working in the home infusion industry since 2009. She has authored numerous abstracts and publications related to nutrition support, outcomes, health equity and literacy. Christina is the recipient of the 2021 NHIF Outstanding Abstract Award and 2022 ASPEN Home Parenteral and Enteral Nutrition Trailblazer award. Christina serves on the NHIA Clinical Practice Committee and ASPEN Publications and Membership Committees. She is also the President of the Texas Alamo Society of Parenteral and Enteral Nutrition.

    No Disclosures to Report

    Yoselin Flores

    PGY-1 Resident

    Option Care Health

    Hello, my name is Yoselin Flores, and I am the current PGY-1 Pharmacy Resident at Option Care Health in Itasca, IL. I completed my Doctor of Pharmacy at the University of Illinois at Chicago.  At the conclusion of my residency, I hope to continue my role as a clinical pharmacist in the home infusion field.  

    No Disclosures to Report

    Ruth Taylor, MS, RD, LD

    Nutrition Support Dietitian

    Optum Infusion Pharmacy

    Ruth Taylor is a registered dietitian with 13 years of experience. For the last 9 years she has been working as a nutrition support dietitian with Optum Infusion Pharmacy focusing on enteral nutrition patients. She currently serves on the enteral nutrition committee for A.S.P.E.N. She lives in Fairhope, Alabama with her husband and daughter. 

    No Disclosure to Report

    Amanda Scippa, RD, LDN, CNSC

    Infusion Support Dietitian Director

    KabaFusion

    Amanda Scippa, RD, LDN, CNSC is the Infusion Support Dietitian Director at KabaFusion. She obtained her Bachelor of Science in Nutrition at the University of Massachusetts Amherst and went on to complete her dietetic internship at Brigham and Women's Hospital (BWH) in Boston. After working in the Burn and Trauma Unit at BWH for several years, she decided to transition to the home infusion setting with the goal of helping patients that require long term nutrition support and striving for more holistic care of home infusion patients.

    No Disclosures to Report

  • Contains 4 Component(s), Includes Credits

    Cleaning. The term sounds simple enough. Yet, when applied to sterile compounding areas, the term becomes complex. It not only covers the mechanical act of cleaning but the selection and application of different, essential agents.

    Cleaning. The term sounds simple enough. Yet, when applied to sterile compounding areas, the term becomes complex. It not only covers the mechanical act of cleaning but the selection and application of different, essential agents. Additionally, procedures for the act of cleaning and a schedule determining when and which items and areas are cleaned, are essential to compounding operations. The 2021 version of USP General Chapter <797> improved upon the language surrounding the agents used in sterile compounding areas, but there is still confusion around what the agents do and what defines an appropriate agent. This article explores the agents used to meet the cleaning requirements of USP General Chapter <797> and does not address deactivation and decontamination, as required by USP General Chapter <800>.

    Learning Objectives:

    1. Distinguish between cleaning (removing soil load) and disinfecting (killing microorganisms).
    2. Be able to determine which type of agent to use for daily, optional weekly, and monthly cleaning in your own sterile compounding environment.
    3. Understand the advantages and disadvantages of several common agents used in sterile compounding areas.

    Abby Roth, BS, CMQ/OE

    Founder

    Pure Microbiology

    Abby Roth, founder of Pure Microbiology, has over 18 years of experience in supporting the testing and consulting needs of the pharmaceutical, medical device, and compounding industries. Her background in pharmaceutical microbiology includes extensive knowledge of environmental monitoring. Abby served as a USP Compounding EC member during the 2015-2020 cycle. She is an involved member of the Controlled Environment Testing Association (CETA), serving on the Board of Directors, speaking at its annual meetings, and chairing committees for the revision of four CETA Application Guides. Abby has been invited to speak for state boards of pharmacy and for national organizations.

    No Disclosures to Report

  • Contains 4 Component(s), Includes Credits

    Multi-drug resistant tuberculosis (MDR-TB) has become a leading world health crisis. MDR-TB is defined as resistance to the potent cornerstone TB drugs, isoniazid and rifampin. Approximately, 3% of newly infected cases and 20% of pre-existing TB cases are diagnosed with MDR-TB.

    Multi-drug resistant tuberculosis (MDR-TB) has become a leading world health crisis. MDR-TB is defined as resistance to the potent cornerstone TB drugs, isoniazid and rifampin. Approximately, 3% of newly infected cases and 20% of pre-existing TB cases are diagnosed with MDR-TB. 

    In recent years, aminoglycosides have become a part of the backbone of MDR-TB treatments. The most common aminoglycosides used for pulmonary TB are amikacin and streptomycin. Despite the lack of data on specific amikacin dosing and duration of treatment, it is still widely used as an add-on therapy in non-responsive MDR-TB patients. This article will review amikacin dosing and its use based on current guidelines; explore amikacin pharmacokentics and pharmacodynamics and dosing; explore the relationship between aminoglycosides and ototoxicity; and distinguish between monitoring methods in the home infusion setting.  

    LEARNING OBJECTIVES:

    1. Provide an overview of tuberculosis, multi-drug resistant tuberculosis (MDR-TB), and history of amikacin use.
    2. Understand aminoglycoside dosing and its use based on current guidelines.
    3. Comprehend amikacin pharmacokinetics and pharmacodynamics.
    4. Appreciate the relationship between aminoglocosides and ototoxicity.
    5. Distinguish between monitoring methods in the home infusion setting.

    Vy Dang

    PharmD

    Optum Infusion Services

    Vy Dang, Pharm.D, HDDP is an Infusion Clinical Pharmacist at Optum Infusion Services in Wallingfor, Connecticut. She earned a Bachelor’s degree in Health Sciences at University of California, Irvine and a Doctor of Pharmacy degree at Roseman University of Health Sciences College of Pharmacy. Dang was a pharmacy practice resident in Las Vegas. She has practiced in infectious disease, genetics, oncology, and emergency medicine. Her current practice focuses on parenteral nutrition, acute care, inotropes, IV anti-infective agents, and pain management. She also provides clinical care for high-cost IV drugs including immunoglobulins (IGs), enzyme replacement therapies (eg. Fabrazyme), Radicava, Solaris, Entyvio, biologics, and alpha-1 proteinase inhibitors (eg. Glassia, Zemaira). Dang is currently licensed in Arizona, Connecticut, Massachusetts, Nevada and Ohio.

    No Disclosures to Report

  • Contains 1 Component(s)

    Pharmacist professional services are paramount to the success of the home infusion process.

    Pharmacist professional services are paramount to the success of the home infusion process. Even though there is a general understanding of the type and scope of care that a pharmacist provides, the various tasks and how they differ between therapy types and drug administration method are unknown. Using home infusion pharmacist time utilization data collected in this study, the amount of time the home infusion pharmacist spends managing and caring for the patient was determined. The categories of professional services the pharmacist provides and the time and task differences between therapy types and methods of administration was also determined. 

    Danell Haines

    Research Consultant

    NHIA

    Danell Haines, received her doctorate from The Ohio State University and now serves as a research consultant for the NHIA/NHIF. Currently, Dr. Haines is assisting the NHIF with the much talked about "Multi-center Time Study of Home Infusion Pharmacist Professional Services" and was instrumental in the development and validation of the Uniform Patient Satisfaction Survey Questions for Home Infusion Providers. Prior to her retirement from Ohio State, she served as a Research Scientist for the Department of Family Medicine and was Director for the National Research Institute for College Recreational Sports and Wellness. As a Research Scientist, Dr. Haines oversaw the research curriculum for the Family Medicine residents and wrote research protocols and grants. She also has publications and presentations on how to conduct research, write research manuscripts, and grant proposals. Dr. Haines enjoys analyzing and reporting benchmarking data, mentoring novice researchers, and guiding professionals through the research process.

    No Disclosures to Report

    Ryan Garst, PharmD, MBA, IgCP, BCSCP

    Sr Director Clinical Services

    NHIA

    Ryan Garst, Pharm D, MBA, BCSCP is the Senior Director of Clinical Services at the National Home Infusion Association. Garst has almost 15 years of experience in home infusion and nearly twenty years of experience in pharmacy clinical and operational leadership and management, information technology, sales, and clinical practice experience. At NHIA, Garst is responsible for clinical education and services, Infusion Magazine Clinical Editor, and oversees a variety of programs administered by the National Home Infusion Foundation including the industry resident program, the National Benchmarking Program, and clinical trials and research. Prior to joining NHIA, Garst served on a variety of committees for the association and participated in numerous annual conferences. Garst holds a Doctor of Pharmacy degree from Ohio Northern University and a Master of Business Administration from Kent State University and is Board Certified in Sterile Compounded Preparations via BPS.

    No Disclosures to Report

    Connie Sullivan

    President & CEO

    National Home Infusion Association

    Connie Sullivan, B.S.Pharm, is the President and CEO of NHIA. Sullivan has over 25 years of infusion industry leadership, management, and clinical practice experience. Sullivan is responsible for NHIA’s advocacy initiatives and developing resources that support the infusion industry to foster innovation and promote the delivery of high-quality care. Sullivan also oversees the National Home Infusion Foundation, a 501c3 devoted to infusion research and developing future leaders. Sullivan is a member of the United States Pharmacopeia (USP) Sterile Compounding Expert Committee and currently Chairs the <797> Subcommittee. Sullivan earned her pharmacy degree from The Ohio State University in 1994.

    No Disclosures to Report

    Jennifer Charron

    RN, MSN, MBA

    NHIA

    Jennifer Charron, RN, MSN, MBA, NHIA’s Chief Operating Officer, is primarily focused on meeting the membership needs for the association.  In this position she oversees the annual conference, member engagement, NHIA operations, and educational programing. Charron holds master’s in nursing education as well as an MBA specializing in health care leadership.  Charron has been a nurse for over 20 years, focusing the last 15 years in home infusion where she oversaw clinical and operational aspects of business for a large regional home infusion provider.  Her varied experience in this expanding market includes 503A and 503B pharmacies, clinical program development, business expansion, and regulatory compliance.   In addition to her work creating new educational programming for NHIA members, Charron is also involved in the organization’s government relations, provider outreach, and foundation activities.    

    No Disclosures to Report

  • Contains 4 Component(s), Includes Credits Recorded On: 09/20/2023

    This presentation will focus on the process of evaluating stability studies of parenteral drugs as a critical step in determining an appropriate beyond-use date for a compounded sterile preparation.

    When the usage timeframe in the manufacturer product labeling is limited or omitted, published stability studies can potentially support extending the beyond-use date assigned to a compounded sterile preparation. This presentation will focus on the process of evaluating stability studies of parenteral drugs as a critical step in determining an appropriate beyond-use date for a compounded sterile preparation. 

    Learning Objectives:

    1. Navigate the literature resources and review drug stability studies for validity.
    2. Assess the applicability of a drug stability study to assigning a beyond-use date to a compounded sterile preparation.
    3. Differentiate the changes made in USP <797>, analyze how these impact the beyond-use date. 

    Michelle Simpson, PharmD, BCSCP, MWC

    Clinical Program Manager

    National Home Infusion Association

    Michelle C. Simpson, PharmD, BCSCP, MWC, is a Board Certified Sterile Compounding Pharmacist with an established career in home infusion. She is the Clinical Program Manager for the National Home Infusion Association (NHIA), where she is responsible for research studies, non-profit foundation initiatives, data benchmarking, and clinical education development. Michelle is Editor in Chief of Infusion Journal, a peer-reviewed scholarly publication that features independent original research on infusion therapies and is published by the National Home Infusion Foundation (NHIF). Michelle is Co-Editor of Extended Stability for Parenteral Drugs, 7th Edition, a publication of the American Society of Health-System Pharmacists (ASHP). 

    No Disclosures to Report

    Christpher Roy, PharmD, BCSCP

    Pharmacist Training Specialist

    Option Care Health

    Chris Roy, PharmD, BCSCP, began his career with Option Care Health in 2018 as a PGY-1 resident. Since that point, he has held roles as a Clinical Pharmacist, Pharmacy Supervisor, and currently is the Pharmacist Training Specialist with Option Care Health. Chris believes that proper training and education are key to the future of the pharmacy profession and necessary to further the home infusion industry.

    No Disclosures to Report

  • Contains 4 Component(s), Includes Credits

    Refeeding Syndrome (RS) has historically been defined as a range of metabolic and electrolyte disturbances that occur after the reintroduction of calories after a period of minimal or no calorie intake. 1 CE

    Refeeding Syndrome (RS) has historically been defined as a range of metabolic and electrolyte disturbances that occur after the reintroduction of calories after a period of minimal or no calorie intake. This continuing education article will review RS from its history and pathophysiology to the recent ASPEN 2020 Consensus Recommendations which have redefined RS, established criteria for identifying at risk patients, and updated recommendations for prevention and treatment of patients at RS risk focusing on the adult patient.

    Learning Objectives:

    1. Define and describe the pathophysiology of refeeding syndrome.
    2. Describe signs and symptoms of refeeding syndrome.
    3. List criteria included in ASPEN's 2020 adult refeeding syndrome risk assessment.
    4. Describe steps to prevent refeeding syndrome in at risk adult patients.

    Lisa Kinder, RD, CNSC

    West Region Nutrition Support Dietitian

    Optum Infusion Pharmacy

    Lisa Kinder RD, CNSC, is the West Region Nutrition Support Dietitian at Optum Infusion Pharmacy. She has been a registered dietitian for 19 years; has worked exclusively in the home infusion setting caring for parenteral nutrition patients for 16 years; and has maintained certification as a nutrition support clinician for over 15 years. Kinder has co-authored and presented several posters at ASPEN and NHIA and was a podium presenter at NHIA’s annual conference in 2017. She was honored with a Sages of Clinical Service Award from United Health Group in 2019.  

    No Disclosures to Report

    Shirley Au, RD, CNSC

    West Regional Nutrition Support Dietitian

    Optum Infusion Pharmacy

    Shirley Au, RD CNSC is the West Regional Nutrition Support Dietitian at Optum Infusion Pharmacy. She has extensive experience in home infusion, specializing in nutrition support business development and patient care management. She began her home infusion career in 2004 and has held leadership positions with several national providers. Au has published several journal articles and presented posters at ASPEN's annual conference. She has also been honored by her peers as a Dietitian Top Performer, Clinician of the Year, and Everyday Hero. 

    No Disclosures to Report

    Penny Allen, RD, CNSC

    National Director Nutrition Support

    Optum Infusion Pharmacy

    Penny Allen RD CNSC FASPEN FNHIAis the National Director, Nutrition Support for Optum Infusion Pharmacy. Pennybegan her nutrition support career at Beth Israel Hospital in Boston, Massachusettsafter obtaining her nutrition degree from the University of New Hampshire. Shehas spent over 30 years in the home infusion setting in a variety of roles,currently serving as a nutrition support program lead for Optum InfusionPharmacy. She is a Certified Nutrition Support Clinician (CNSC), serves asImmediate Past Chair of the ASPEN Public Policy Committee, current Chair of theNational Home Infusion’s Medicare Contractor and Advisory Committee and is apublished subject matter expert in Medicare PN and EN policies and other homenutrition support related topics. 

    No Disclosures to Report

  • Contains 4 Component(s), Includes Credits Recorded On: 11/14/2023

    We will take a look at various concepts related to biosimilars including transition from the parent product to a biosimilar, determining what is interchangeable, and more.

    What is the future of biosimilars in the home and alternate site? There are numerous options now available and even now interchangeable options. We will take a look at various concepts related to biosimilars including transition from the parent product to a biosimilar, determining what is interchangeable, and more. 

    Learning Objectives:

    1. Review the legislative impact for pharmacies as it relates to interchangeability of approved molecules in clinical practice. 
    2. Review current requirements for FDA approval of biosimilars and interchangeability requirements for biosimilars.
    3. Describe potential processes to overcome barriers to biosimilar adoption (prescribing, financial, operational).

    Jonathan Ogurchak, PharmD, CSP

    Co-Founder & CEO

    STACK

    Jonathan Ogurchak is the Founder & CEO of STACK, a compliance management software designed to simplify the “outside of the dispense” complexities associated with running successful pharmacy organizations. He is also Managing Partner of Rhythm Group, consulting and technology solutions organization, and is a Certified Consultant with Accreditation Commission for Health Care (ACHC). Jonathan has designed programs and services for both Accredo and PANTHERx Specialty Pharmacy focusing on implementing innovative uses for technology, including high-touch pharmacist-driven programs focused on dosing efficiency, clinical monitoring of patient outcomes, and integrated patient engagement. Jonathan is on faculty for the Master of Pharmacy Business Administration (MPBA) program through the University of Pittsburgh, leading the Specialty Pharmacy Management curriculum. He currently serves on the editorial board for Specialty Pharmacy Times, holds CSP Certification through the Specialty Pharmacy Certification Board, and serves as an Educational Consultant for the National Association of Specialty Pharmacy (NASP). 

    No Disclosures to Report